- Home
- EYPT vs CRON Comparison
EYPT vs CRON Comparison
Compare EYPT & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | CRON |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EYPT | CRON |
|---|---|---|
| Price | $13.36 | $2.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $31.80 | N/A |
| AVG Volume (30 Days) | 786.6K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $146,587,000.00 |
| Revenue This Year | N/A | $26.34 |
| Revenue Next Year | $3,115.57 | $15.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.63 |
| 52 Week Low | $5.46 | $1.81 |
| 52 Week High | $19.11 | $3.43 |
Technical Indicators
Market Signals| Indicator | EYPT | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 51.36 |
| Support Level | $12.47 | $2.47 |
| Resistance Level | $13.32 | $2.73 |
| Average True Range (ATR) | 0.63 | 0.14 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 27.50 | 15.28 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.